AndyForce-CureBio to Promote Transfer of C-Vax Material Applicable to COVID-19 Vaccine Development

[Asia Economy Reporter Hyungsoo Park] AndyForce announced on the 25th that CureBio is promoting the transfer of the autoimmune substance C-Vax, which was independently discovered by the Biomedical Convergence Research Group (BIOCON).

According to the Biomedical Convergence Research Group, this substance has already proven therapeutic effects against the human papillomavirus that causes cervical cancer. Using the same principle, it plans to apply it to the development of a novel coronavirus (COVID-19) vaccine, and in the future, it will proceed with the development of vaccines for various diseases as a substance applicable to virus and cancer vaccines.

CureBio, which is developing the substance of the research group led by Dr. Seonghoon Kim of Yonsei University College of Pharmacy as a new drug, is actively developing lung cancer treatments and coronavirus therapeutics based on siRNA technology. The transfer of the C-Vax substance, which can be applied to COVID-19 vaccine development, is also underway.

Established in 2010, the Biomedical Convergence Research Group started as an industry-academia research group at Seoul National University College of Pharmacy, aiming to build a high-efficiency new drug development platform that can effectively link the process from new drug target discovery to candidate substance derivation, thereby reforming the cost, duration, and success rate of new drug development.

Since the MERS outbreak in 2015, the research group has conducted basic research for the development of antiviral treatments and vaccines as well as anticancer therapies. Recently, they discovered the human autoimmune substance C-Vax and are developing it as a platform to enhance the efficacy of virus and anticancer vaccines. C-Vax is expected to be widely used as a safe immune-activating substance without side effects for the development of vaccines for virus and cancer treatment.

A company official stated, “The research group has specialized in developing new mechanism targets for new drug development over the past 10 years and has published about 100 world-class academic papers in top journals such as Science, Cell, and the Nature series, recognized as a research group with high research capabilities in new drug target development.” He added, “CureBio will accelerate its new drug development business through the promotion of the transfer of the C-Vax substance independently discovered by the research group.”

This content was produced with the assistance of AI translation services.